Answers are grounded in this paper and cite their sources.
Review explores the role of oral microbiota in cancer progression and potential therapeutic targets for OSCC, highlighting implications for treatment.
Introduction/Background: Oral Squamous Cell Carcinomas (OSCC) are one of the common causes of death globally. Several etiological factors cause OSCC, including alcohol, tobacco use, poor oral hygiene, Human Papilloma Virus (HPV) infections, Yeast (Candida spp.) infections, etc. Oral microbial dysbiosis and inflammatory conditions like periodontitis have also been implicated recently. The host-microbiome interactions may further alter the homeostasis of the oral Tumor Microenvironment (TME). In this review, we aim to determine the role of resident microbiota in oral cancer progression and decipher how they interact with the TME. The article also discusses potential biomarkers and therapeutic targets to enhance the management of OSCC. Methods: PubMed, Medline, and Google Scholar were used as biomedical literature databases. The following keywords were looked up for academic literature using Boolean operators. Initially, a total of 273 articles were found as a result of the literature search. Results: Finally, 142 articles that met the exclusion and inclusion criteria were chosen for literature review, as depicted in the PRISMA flowchart. Discussion: Multiple oral bacterial species are linked to OSCC. Modulation immunotherapies that target the TME and reverse oral microbiota dysbiosis have been proposed in recent investigations. Changes in the oral microbiota have an impact on the oral microenvironment, leading to inflammatory cell infiltration, cytokine release, and chronic inflammation. All the data support an immunosuppressive TME. Antifungal and antibacterial medications are currently advised for the treatment. Conclusion: We conclude that the utilization of microbial biomarkers and generated products as potential anticancer targets could be one of the methods for mitigating oral cancer. Tumor immunotherapies are the newest method for treating cancer patients. However, there are still a lot of drawbacks. We attempted to outline the possible approaches to potential immunotherapies.
No takes yet. Share an insight, caveat, or question.
Goswami et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: